Mylan, a part of Pennsylvania-headquartered global healthcare company Viatris, exited Biocon, the biopharmaceutical company, by selling its entire 5.64 percent shareholding via block deals on July 13.
Biocon shares rallied 6.4 percent to Rs 437.3 amid high volumes on the National Stock Exchange, may be reacted to the 5.64 percent shares bought by global and domestic institutional investors from Mylan.
As per the block deals data, on Tuesday, Mylan sold 4.59 crore shares each in Biocon on the National Stock Exchange and BSE, valued at Rs 3,678.68 crore.
The price at which 5.64 percent shares exchanged was Rs 400 per share.
ICICI Prudential Mutual Fund was the largest buyer among 36 investors, picking up 3.68 crore equity shares (2.26 percent stake) in Biocon for Rs 1,475 crore.
This follows Kotak Mahindra Mutual Fund, and HDFC Mutual Fund which each acquired 1.15 crore shares (0.71 percent stake) in the pharma company for Rs 463.82 crore.
Other marquee domestic names invested in Biocon were Abakkus, WhiteOak Capital Mutual Fund, Aditya Birla Sun Life MF, Axis Mutual Fund, SBI Mutual Fund, Franklin Templeton MF, HDFC Life Insurance Company, ICICI Prudential Life Insurance, Mirae Asset MF, and Motilal Oswal AMC.
Global investors like Citigroup, Eastspring Investments, Goldman Sachs, Morgan Stanley, Societe Generale, and Vanguard Emerging Markets also participated in the block deals.